Literature DB >> 9549653

Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers.

A C Rudy1, Y Liu, C Brater, S D Hall.   

Abstract

The pharmacokinetics of ketoprofen enantiomers were evaluated after 25-, 50-, and 100-mg doses of (R)- ketoprofen and 100 mg of racemic ketoprofen in 25 healthy volunteers (12 male and 13 female). The fractional inversion (Finv) of (R)- ketoprofen was 8.9 +/- 3.3% using plasma data and 10.0 +/- 2.2% using urine data. There were small (< 5%) but significant differences between the enantiomers for areas under the plasma concentration-time curve (AUC) after the racemic dose (P < 0.005). Half-lives were 130-144 minutes for (R)- ketoprofen and 132-209 minutes for (S)- ketoprofen. Dose proportionality in AUC and maximum plasma concentration (Cmax) values was noted for both enantiomers. A total of 69% of the dose was recovered in the urine as (R)- and (S)- ketoprofen and conjugates. The elimination rate constant of (R)- ketoprofen was significantly different (P < 0.05) between men and women. Exposure to cyclooxygenase inhibiting (S)- ketoprofen was approximately 10% of the dose after the administration of pure (R)- ketoprofen and was independent of gender.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549653     DOI: 10.1002/j.1552-4604.1998.tb04411.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.

Authors:  Fried Faassen; Herman Vromans
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Influence of Sex and Food on the Bioavailability and the R-to-S Conversion of Ketoprofen Stereoisomers in Humans.

Authors:  Pietro Fagiolino; Nikoletta Fotaki; Marta Vázquez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

4.  Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

Authors:  N G Grubb; D W Rudy; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains.

Authors:  Da Shi; Yin-xiu Jin; Yi-hong Tang; Hai-hong Hu; Si-yun Xu; Lu-shan Yu; Hui-di Jiang; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

7.  Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.

Authors:  Marianela Lorier; Laura Magallanes; Manuel Ibarra; Natalia Guevara; Marta Vázquez; Pietro Fagiolino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.